Pharmacological Profile for the Contribution of NO/cGMP Pathway on Chlorpheniramine Antidepressant-Like Effect in Mice Forced Swim Test
Chlorpheniramine, a first-generation antihistamine, is widely used for allergic reactions. Previous studies showed the interaction between antidepressant activity and nitric oxide and cyclic guanosine monophosphate (NO/cGMP) pathway. Thus, we aimed to assess the possible involvement of NO/cGMP pathw...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tehran University of Medical Sciences
2018-11-01
|
| Series: | Acta Medica Iranica |
| Subjects: | |
| Online Access: | https://acta.tums.ac.ir/index.php/acta/article/view/6933 |
| _version_ | 1818206927705866240 |
|---|---|
| author | Saeed Shakiba Nazanin Rajai Mehdi Qaempanah Nazgol‐Sadat Haddadi Abbas Norouzi-Javidan Reyhaneh Akbarian Sattar Ostadhadi Ahmad-Reza Dehpour |
| author_facet | Saeed Shakiba Nazanin Rajai Mehdi Qaempanah Nazgol‐Sadat Haddadi Abbas Norouzi-Javidan Reyhaneh Akbarian Sattar Ostadhadi Ahmad-Reza Dehpour |
| author_sort | Saeed Shakiba |
| collection | DOAJ |
| description | Chlorpheniramine, a first-generation antihistamine, is widely used for allergic reactions. Previous studies showed the interaction between antidepressant activity and nitric oxide and cyclic guanosine monophosphate (NO/cGMP) pathway. Thus, we aimed to assess the possible involvement of NO/cGMP pathway in this effect using forced swim test (FST) in male mice. To evaluate the locomotor activity and immobility time, we performed open field test (OFT) and FST on each mouse. Chlorpheniramine was administered intraperitoneally (i.p.) (0.1, 0.3, 1, 10 mg/kg) 30 minutes before FST. To assess the involvement of NO/cGMP pathway, a non-selective nitric oxide synthase (NOS) inhibitor, L-NAME (10mg/kg, i.p.), a selective inducible NOS (iNOS) inhibitor, aminoguanidine (50 mg/kg, i.p.), a selective neural NOS (nNOS) inhibitor, 7-nitroindazole (7-NI, 30 mg/kg, i.p.), a NO precursor, L-arginine (750 mg/kg, i.p.) and a selective phosphodiesterase-5 (PDE-5) inhibitor, sildenafil (5 mg/kg, i.p.) was co-administered with chlorpheniramine. Chlorpheniramine significantly decreased the immobility time at doses of 1mg/kg (P<0.01) and 10 mg/kg (P<0.001). Administration of L-NAME (P<0.01) and 7-NI enhanced the anti-immobility activity of chlorpheniramine (P<0.001), while aminoguanidine did not have any significant effects on the immobility time (P>0.05). Moreover, pretreatment with L-arginine (P<0.01) and sildenafil (P<0.001) significantly reduced the anti-immobility effect of chlorpheniramine. These treatments did not alter the locomotor activity of mice in OFT. Our results revealed that the antidepressant-like effect of chlorpheniramine is mediated through inhibition of NO/cGMP pathway. |
| first_indexed | 2024-12-12T04:20:48Z |
| format | Article |
| id | doaj.art-0f2f714ca9ab423690b709c2fb75bc38 |
| institution | Directory Open Access Journal |
| issn | 0044-6025 1735-9694 |
| language | English |
| last_indexed | 2024-12-12T04:20:48Z |
| publishDate | 2018-11-01 |
| publisher | Tehran University of Medical Sciences |
| record_format | Article |
| series | Acta Medica Iranica |
| spelling | doaj.art-0f2f714ca9ab423690b709c2fb75bc382022-12-22T00:38:19ZengTehran University of Medical SciencesActa Medica Iranica0044-60251735-96942018-11-015686933Pharmacological Profile for the Contribution of NO/cGMP Pathway on Chlorpheniramine Antidepressant-Like Effect in Mice Forced Swim TestSaeed Shakiba0Nazanin Rajai1Mehdi Qaempanah2Nazgol‐Sadat Haddadi3Abbas Norouzi-Javidan4Reyhaneh Akbarian5Sattar Ostadhadi6Ahmad-Reza Dehpour7Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. AND Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. AND Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. AND Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. AND Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. AND Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. AND Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. AND Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.Chlorpheniramine, a first-generation antihistamine, is widely used for allergic reactions. Previous studies showed the interaction between antidepressant activity and nitric oxide and cyclic guanosine monophosphate (NO/cGMP) pathway. Thus, we aimed to assess the possible involvement of NO/cGMP pathway in this effect using forced swim test (FST) in male mice. To evaluate the locomotor activity and immobility time, we performed open field test (OFT) and FST on each mouse. Chlorpheniramine was administered intraperitoneally (i.p.) (0.1, 0.3, 1, 10 mg/kg) 30 minutes before FST. To assess the involvement of NO/cGMP pathway, a non-selective nitric oxide synthase (NOS) inhibitor, L-NAME (10mg/kg, i.p.), a selective inducible NOS (iNOS) inhibitor, aminoguanidine (50 mg/kg, i.p.), a selective neural NOS (nNOS) inhibitor, 7-nitroindazole (7-NI, 30 mg/kg, i.p.), a NO precursor, L-arginine (750 mg/kg, i.p.) and a selective phosphodiesterase-5 (PDE-5) inhibitor, sildenafil (5 mg/kg, i.p.) was co-administered with chlorpheniramine. Chlorpheniramine significantly decreased the immobility time at doses of 1mg/kg (P<0.01) and 10 mg/kg (P<0.001). Administration of L-NAME (P<0.01) and 7-NI enhanced the anti-immobility activity of chlorpheniramine (P<0.001), while aminoguanidine did not have any significant effects on the immobility time (P>0.05). Moreover, pretreatment with L-arginine (P<0.01) and sildenafil (P<0.001) significantly reduced the anti-immobility effect of chlorpheniramine. These treatments did not alter the locomotor activity of mice in OFT. Our results revealed that the antidepressant-like effect of chlorpheniramine is mediated through inhibition of NO/cGMP pathway.https://acta.tums.ac.ir/index.php/acta/article/view/6933ChlorpheniramineNitric oxideCyclic guanosine monophosphateForced swim testMice |
| spellingShingle | Saeed Shakiba Nazanin Rajai Mehdi Qaempanah Nazgol‐Sadat Haddadi Abbas Norouzi-Javidan Reyhaneh Akbarian Sattar Ostadhadi Ahmad-Reza Dehpour Pharmacological Profile for the Contribution of NO/cGMP Pathway on Chlorpheniramine Antidepressant-Like Effect in Mice Forced Swim Test Acta Medica Iranica Chlorpheniramine Nitric oxide Cyclic guanosine monophosphate Forced swim test Mice |
| title | Pharmacological Profile for the Contribution of NO/cGMP Pathway on Chlorpheniramine Antidepressant-Like Effect in Mice Forced Swim Test |
| title_full | Pharmacological Profile for the Contribution of NO/cGMP Pathway on Chlorpheniramine Antidepressant-Like Effect in Mice Forced Swim Test |
| title_fullStr | Pharmacological Profile for the Contribution of NO/cGMP Pathway on Chlorpheniramine Antidepressant-Like Effect in Mice Forced Swim Test |
| title_full_unstemmed | Pharmacological Profile for the Contribution of NO/cGMP Pathway on Chlorpheniramine Antidepressant-Like Effect in Mice Forced Swim Test |
| title_short | Pharmacological Profile for the Contribution of NO/cGMP Pathway on Chlorpheniramine Antidepressant-Like Effect in Mice Forced Swim Test |
| title_sort | pharmacological profile for the contribution of no cgmp pathway on chlorpheniramine antidepressant like effect in mice forced swim test |
| topic | Chlorpheniramine Nitric oxide Cyclic guanosine monophosphate Forced swim test Mice |
| url | https://acta.tums.ac.ir/index.php/acta/article/view/6933 |
| work_keys_str_mv | AT saeedshakiba pharmacologicalprofileforthecontributionofnocgmppathwayonchlorpheniramineantidepressantlikeeffectinmiceforcedswimtest AT nazaninrajai pharmacologicalprofileforthecontributionofnocgmppathwayonchlorpheniramineantidepressantlikeeffectinmiceforcedswimtest AT mehdiqaempanah pharmacologicalprofileforthecontributionofnocgmppathwayonchlorpheniramineantidepressantlikeeffectinmiceforcedswimtest AT nazgolsadathaddadi pharmacologicalprofileforthecontributionofnocgmppathwayonchlorpheniramineantidepressantlikeeffectinmiceforcedswimtest AT abbasnorouzijavidan pharmacologicalprofileforthecontributionofnocgmppathwayonchlorpheniramineantidepressantlikeeffectinmiceforcedswimtest AT reyhanehakbarian pharmacologicalprofileforthecontributionofnocgmppathwayonchlorpheniramineantidepressantlikeeffectinmiceforcedswimtest AT sattarostadhadi pharmacologicalprofileforthecontributionofnocgmppathwayonchlorpheniramineantidepressantlikeeffectinmiceforcedswimtest AT ahmadrezadehpour pharmacologicalprofileforthecontributionofnocgmppathwayonchlorpheniramineantidepressantlikeeffectinmiceforcedswimtest |